# Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

> clinical trial · VERIFIED · 2026-07-28

Status: NOT_YET_RECRUITING · Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) · Condition: Post-Acute COVID-19 Syndrome

- Company: National Institute of Neurological Disorders and Stroke (NINDS)
- Sector: neurotech
- Primary source: https://clinicaltrials.gov/study/NCT07388550

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.